Stage of compensation/stage of decompensation: cirrhosis, liver failure.
Conditions
Interventions
Liver failure:None
Stage of compensation/stage of decompensation in cirrhosis.:None
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18 to 75 years old, both males and females are eligible; 2. Patients with hepatic failure (severe): meet either criterion (1) or (2). (1) ACLF: develops within 4 weeks on top of chronic liver disease with total serum bilirubin >= 5 mg/dL (85 µmol/L) and coagulation dysfunction (INR >= 1.5); (2) SACLF: develops within 4-24 weeks on top of chronic liver diseases with total serum bilirubin > 5 mg/dL (85µmol/L) and impaired coagulation (INR >=1.5); 3. Patients with decompensated cirrhosis (moderate): meet criterion (1) or (2), with criterion (3) being mandatory; (1) Imaging (abdominal ultrasound/CT/MRI) shows cirrhosis. (2) Fibroscan (F >= 12.4 kPa) or a liver histological fibrosis score of F4 (Ishak scoring system) or higher; (3) Development of complications related to decompensation: ascites/esophageal/gastric varices rupture/hepatic encephalopathy. 4. Patients with compensated cirrhosis (mild): meet criterion (1) or criterion (2), with the addition of criterion (3). (1) Imaging shows cirrhosis (abdominal ultrasound, CT, or MRI); (2) Fibroscan shows F >= 12.4kPa or liver histology shows F4 (Ishak scoring) or higher; (3) No complications related to decompensation: no ascites, no esophageal/gastric variceal rupture, no hepatic encephalopathy.
Exclusion criteria
Exclusion criteria: 1. Acute liver failure; 2. Post-TIPS surgery; 3. Comorbidity with severe cardiopulmonary or renal dysfunction or malignant tumors; 4. Comorbidity with HIV infection; 5. Pregnancy or lactation; 6. Hypersensitivity to iodine; 7. Allergic constitution; 8. Uncorrectable hypoxemia; 9. Unstable vital signs; 10. Active gastrointestinal bleeding; 11. Inability to remain still during examinations; 12. The investigator deems the individual unsuitable for inclusion in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Volatile Organic Compounds ;Liver reserve function testing result; | — |
Secondary
| Measure | Time frame |
|---|---|
| Fibroscan datas;Abdominal ultrasound/abdominal MRI/CT datas; | — |
Countries
China
Contacts
Public ContactHongTang
West China Hospital of Sichuan University
Outcome results
None listed